Javelin Pharmaceuticals To Present Final Analysis Of Phase 2b Study Results Of Dyloject(TM) At Prestigious European Pain Conference - September 14th 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 12, 2006--Javelin Pharmaceuticals, Inc. (Amex:JAV), today announced that Daniel B. Carr, MD, Chief Executive Officer and Chief Medical Officer, will present the final results from Company's Phase 2b (DFC-002) study of Dyloject during a poster session at the 5th Congress of The European Federation of International Association for the study of Pain Chapters. The presentation is scheduled for September 14, 2006 from 16:00 p.m. to 16:45 p.m. EEST at the Istanbul Convention & Exhibition Centre (ICEC) Harbiye 80230 Istanbul, Turkey.